Avacta Group Plc (AIM:AVCT)

Market Cap	182.68M
Revenue (ttm)	113.00K
Net Income (ttm)	-52.84M
Shares Out	388.68M
EPS (ttm)	-0.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,726,690
Average Volume	3,817,946
Open	50.60
Previous Close	51.50
Day's Range	47.00 - 52.44
52-Week Range	26.00 - 79.50
Beta	-0.30
RSI	64.96
Earnings Date	Jul 3, 2025

About Avacta Group

Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that driv...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 151
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: AVCT

Financial Performance

In 2024, Avacta Group's revenue was 113,000, a decrease of -96.04% compared to the previous year's 2.85 million. Losses were -52.84 million, 58.9% more than in 2023.